A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Studyof Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellula